GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » Cyclically Adjusted PB Ratio

Jafron Biomedical Co (SZSE:300529) Cyclically Adjusted PB Ratio : 9.85 (As of Jun. 09, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co Cyclically Adjusted PB Ratio?

As of today (2024-06-09), Jafron Biomedical Co's current share price is ¥27.49. Jafron Biomedical Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was ¥2.79. Jafron Biomedical Co's Cyclically Adjusted PB Ratio for today is 9.85.

The historical rank and industry rank for Jafron Biomedical Co's Cyclically Adjusted PB Ratio or its related term are showing as below:

SZSE:300529' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 6.25   Med: 8.19   Max: 10.5
Current: 9.87

During the past years, Jafron Biomedical Co's highest Cyclically Adjusted PB Ratio was 10.50. The lowest was 6.25. And the median was 8.19.

SZSE:300529's Cyclically Adjusted PB Ratio is ranked worse than
91.16% of 475 companies
in the Medical Devices & Instruments industry
Industry Median: 2.1 vs SZSE:300529: 9.87

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Jafron Biomedical Co's adjusted book value per share data for the three months ended in Mar. 2024 was ¥3.999. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ¥2.79 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Jafron Biomedical Co Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Jafron Biomedical Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co Cyclically Adjusted PB Ratio Chart

Jafron Biomedical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 8.18

Jafron Biomedical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 8.18 7.98

Competitive Comparison of Jafron Biomedical Co's Cyclically Adjusted PB Ratio

For the Medical Devices subindustry, Jafron Biomedical Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jafron Biomedical Co's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jafron Biomedical Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Jafron Biomedical Co's Cyclically Adjusted PB Ratio falls into.



Jafron Biomedical Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Jafron Biomedical Co's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=27.49/2.79
=9.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jafron Biomedical Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Jafron Biomedical Co's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.999/115.2271*115.2271
=3.999

Current CPI (Mar. 2024) = 115.2271.

Jafron Biomedical Co Quarterly Data

Book Value per Share CPI Adj_Book
201212 2.041 95.237 2.469
201312 1.482 97.624 1.749
201412 0.644 99.000 0.750
201503 0.000 99.900 0.000
201506 0.710 99.500 0.822
201509 0.000 100.500 0.000
201512 0.802 100.600 0.919
201603 0.869 102.200 0.980
201606 0.849 101.400 0.965
201609 1.432 102.400 1.611
201612 1.513 102.600 1.699
201703 1.572 103.200 1.755
201706 1.582 103.100 1.768
201709 1.653 104.100 1.830
201712 1.757 104.500 1.937
201803 1.870 105.300 2.046
201806 1.933 104.900 2.123
201809 2.014 106.600 2.177
201812 2.146 106.500 2.322
201903 2.311 107.700 2.473
201906 2.331 107.700 2.494
201909 2.480 109.800 2.603
201912 2.693 111.200 2.791
202003 2.933 112.300 3.009
202006 2.954 110.400 3.083
202009 3.195 111.700 3.296
202012 3.512 111.500 3.629
202103 3.871 112.662 3.959
202106 3.978 111.769 4.101
202109 3.934 112.215 4.040
202112 4.170 113.108 4.248
202203 4.586 114.335 4.622
202206 4.215 114.558 4.240
202209 4.446 115.339 4.442
202212 4.425 115.116 4.429
202303 4.670 115.116 4.675
202306 4.009 114.558 4.032
202309 3.851 115.339 3.847
202312 3.898 114.781 3.913
202403 3.999 115.227 3.999

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Jafron Biomedical Co  (SZSE:300529) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Jafron Biomedical Co Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Jafron Biomedical Co (SZSE:300529) Business Description

Traded in Other Exchanges
N/A
Address
No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085
Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.
Executives
Li Feng Director
He Xiao Lian Executives
Dong Fan Directors, Directors, and Executives
Ceng Kai Directors, executives
Tang Xian Min Directors, executives
Zhang Ming Yuan Secretary Dong
Fang Li Hua Supervisors
Zhang Guang Hai Directors, executives
Li De Zhi Executives
Lu Shao Zhang Executives

Jafron Biomedical Co (SZSE:300529) Headlines

No Headlines